Laboratory Medicine, Department of Pathology, King Hussein Cancer Center, Amman 11941, Jordan.
Department of Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
Viruses. 2023 Jun 26;15(7):1439. doi: 10.3390/v15071439.
The kinetics of immune responses to various SARS-CoV-2 vaccines in cancer patients were investigated.
In total, 57 cancer patients who received BNT162b2-RNA or BBIBP-CorV vaccines were enrolled. Cellular and humoral immunity were assessed at three-time points, before the first vaccine dose and 14-21 days after the first and second doses. Chemiluminescent microparticle immunoassay was used to evaluate SARS-CoV-2 anti-spike IgG response, and QuantiFERON SARS-CoV-2 kit assessed T-cell response.
Data showed that cancer patients' CD4 and CD8 T cell-median IFN-γ secretion of SARS-CoV-2 antigens increased after the first and second vaccine doses ( = 0.027 and = 0.042). BNT162b2 vaccinees had significantly higher IFN-γ levels to CD4 and CD8 T cell epitopes than BBIBP-CorV vaccinees ( = 0.028). There was a positive correlation between IgG antibody titer and T cell response regardless of vaccine type ( < 0.05).
This study is one of the first to investigate cellular and humoral immune responses to SARS-CoV-2 immunization in cancer patients on active therapy after each vaccine dose. COVID-19 immunizations helped cancer patients develop an effective immune response. Understanding the cellular and humoral immune response to COVID-19 in cancer patients undergoing active treatment is necessary to improve vaccines and avoid future SARS pandemics.
研究癌症患者对各种 SARS-CoV-2 疫苗的免疫反应动力学。
共纳入 57 例接受 BNT162b2-RNA 或 BBIBP-CorV 疫苗的癌症患者。在首次接种疫苗前、首次和第二次接种疫苗后 14-21 天，分别在三个时间点评估细胞和体液免疫。化学发光微粒子免疫分析法用于评估 SARS-CoV-2 抗刺突 IgG 反应，QuantiFERON SARS-CoV-2 试剂盒评估 T 细胞反应。
数据显示，癌症患者的 CD4 和 CD8 T 细胞对 SARS-CoV-2 抗原的 IFN-γ分泌在首次和第二次接种疫苗后增加（=0.027 和=0.042）。与 BBIBP-CorV 疫苗相比，BNT162b2 疫苗接种者对 CD4 和 CD8 T 细胞表位的 IFN-γ水平显著更高（=0.028）。无论疫苗类型如何，IgG 抗体滴度与 T 细胞反应之间均呈正相关（<0.05）。
本研究首次在癌症患者积极治疗期间，在每次接种疫苗后，研究了 SARS-CoV-2 免疫接种的细胞和体液免疫反应。COVID-19 免疫接种帮助癌症患者产生了有效的免疫反应。了解正在接受积极治疗的癌症患者对 COVID-19 的细胞和体液免疫反应对于改进疫苗和避免未来 SARS 大流行是必要的。
